Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 7/20 | 0.37 |
| ▸ | REN | P00797 | 4/20 | 0.33 |
| ▸ | LAP3 | P28838 | 3/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.31 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6165749 | 0.90 | REN (0.36) | CCR1REN | |
| SCHEMBL6168253 | 0.89 | CSNK1E (0.37) | CSNK1ECCR1RENLAP3ANPEP | |
| SCHEMBL6166908 | 0.83 | CSNK1E (0.39) | CSNK1ECCR1RENLAP3ANPEP | |
| SCHEMBL6168667 | 0.83 | CSNK1E (0.39) | CSNK1ECCR1RENLAP3ANPEP | |
| SCHEMBL6168256 | 0.82 | CCR1 (0.41) | CCR1REN | |
| SCHEMBL6168988 | 0.81 | REN (0.35) | CCR1REN | |
| SCHEMBL6168210 | 0.76 | CSNK1E (0.38) | CSNK1ECCR1RENLAP3ANPEP | |
| SCHEMBL6167172 | 0.76 | MAOA (0.46) | CSNK1ECCR1 | |
| SCHEMBL6167138 | 0.75 | F2RL1 (0.36) | CCR1REN | |
| SCHEMBL6168216 | 0.74 | CSNK1E (0.39) | CSNK1ECCR1RENLAP3ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6548671-B2 | Treating autoimmune diseases, inflammatory conditions, allergies, infections, viral diseases, bronchitis, transplant tissue rejection, atherosclerosis, restenosis, HIV infectivity, and granulomatous | PFIZER INC | 2003-04-15 | — | — | US | claimed |
| EP-1252154-A1 | HETEROCYCLIC AMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2002-10-30 | — | — | EP | claimed |
| US-20020132810-A1 | Novel heterocyclic amide derivatives | BROWN MATTHEW F (US) | 2002-09-19 | — | — | US | claimed |
| WO-2001057023-A1 | HETEROCYCLIC AMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2001-08-09 | — | — | WO | claimed |
| EP-1498417-A1 | Heterocyclic amide derivatives | Pfizer Products Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-6548671-B2 | Treating autoimmune diseases, inflammatory conditions, allergies, infections, viral diseases, bronchitis, transplant tissue rejection, atherosclerosis, restenosis, HIV infectivity, and granulomatous | PFIZER INC | 2003-04-15 | — | — | US | disclosed |
| EP-1252154-A1 | HETEROCYCLIC AMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020132810-A1 | Novel heterocyclic amide derivatives | BROWN MATTHEW F (US) | 2002-09-19 | — | — | US | disclosed |
| WO-2001057023-A1 | HETEROCYCLIC AMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132810-A1 | Novel heterocyclic amide derivatives | ARG1, IL4, ARG2 | CSNK1E 1897/4885CCR1 32/4885REN 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.